Date: 2014-07-21
Type of information: Commercialisation agreement
Compound: Zevtera®/Mabelio® (ceftobiprole medocaril)
Company: Basilea Pharmaceutica (Switzerland) Quintiles (USA - NC)
Therapeutic area: Infectious diseases
Type agreement: commercialisation
Action mechanism: Ceftobiprole belongs to the class of antibacterial agents known as cephalosporins. Its broad spectrum activity encompasses Gram-positive and Gram-negative bacteria, including anti-pseudomonal activity similar to cefepime. The rights for ceftobiprole have been transferred back to Basilea from Cilag GmbH International, a Johnson & Johnson company, in February 2011.
Disease: severe community-acquired and hospital-acquired pneumonia
Details: * On July 21, 2014, Basilea Pharmaceutica reports that it has entered into an agreement with Quintiles for the commercialization of Zevtera®/Mabelio® (ceftobiprole medocaril) in Europe. Under the agreement, Quintiles will provide commercial services including a dedicated field force, medical science liaisons, and market access support in selected countries. \"Basilea has the potential opportunity to launch two hospital products in Europe; ceftobiprole followed by isavuconazole in the event of regulatory approval said Ronald Scott, Basilea\'s Chief Executive Officer. We have initially opted to commercialize our products in Europe through Quintiles in order to retain flexibility and to more fully participate in the economic upside of our products. The agreement with Quintiles allows us to scale and optimize our resources during the launch of Zevtera/Mabelio on a country-by-country basis.\"
Financial terms:
Latest news:
